These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 18178863

  • 1. Low-dose targeted complement inhibition protects against renal disease and other manifestations of autoimmune disease in MRL/lpr mice.
    Atkinson C, Qiao F, Song H, Gilkeson GS, Tomlinson S.
    J Immunol; 2008 Jan 15; 180(2):1231-8. PubMed ID: 18178863
    [Abstract] [Full Text] [Related]

  • 2. The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice.
    Sekine H, Kinser TT, Qiao F, Martinez E, Paulling E, Ruiz P, Gilkeson GS, Tomlinson S.
    Arthritis Rheum; 2011 Apr 15; 63(4):1076-85. PubMed ID: 21452327
    [Abstract] [Full Text] [Related]

  • 3. Administration of a soluble recombinant complement C3 inhibitor protects against renal disease in MRL/lpr mice.
    Bao L, Haas M, Kraus DM, Hack BK, Rakstang JK, Holers VM, Quigg RJ.
    J Am Soc Nephrol; 2003 Mar 15; 14(3):670-9. PubMed ID: 12595503
    [Abstract] [Full Text] [Related]

  • 4. Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL/lpr mice.
    Sekine H, Reilly CM, Molano ID, Garnier G, Circolo A, Ruiz P, Holers VM, Boackle SA, Gilkeson GS.
    J Immunol; 2001 May 15; 166(10):6444-51. PubMed ID: 11342671
    [Abstract] [Full Text] [Related]

  • 5. Transgenic expression of a soluble complement inhibitor protects against renal disease and promotes survival in MRL/lpr mice.
    Bao L, Haas M, Boackle SA, Kraus DM, Cunningham PN, Park P, Alexander JJ, Anderson RK, Culhane K, Holers VM, Quigg RJ.
    J Immunol; 2002 Apr 01; 168(7):3601-7. PubMed ID: 11907125
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Excessive matrix accumulation in the kidneys of MRL/lpr lupus mice is dependent on complement activation.
    Bao L, Zhou J, Holers VM, Quigg RJ.
    J Am Soc Nephrol; 2003 Oct 01; 14(10):2516-25. PubMed ID: 14514729
    [Abstract] [Full Text] [Related]

  • 8. A complement C3 inhibitor specifically targeted to sites of complement activation effectively ameliorates collagen-induced arthritis in DBA/1J mice.
    Song H, Qiao F, Atkinson C, Holers VM, Tomlinson S.
    J Immunol; 2007 Dec 01; 179(11):7860-7. PubMed ID: 18025232
    [Abstract] [Full Text] [Related]

  • 9. Effects of complement factor D deficiency on the renal disease of MRL/lpr mice.
    Elliott MK, Jarmi T, Ruiz P, Xu Y, Holers VM, Gilkeson GS.
    Kidney Int; 2004 Jan 01; 65(1):129-38. PubMed ID: 14675043
    [Abstract] [Full Text] [Related]

  • 10. Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B.
    Watanabe H, Garnier G, Circolo A, Wetsel RA, Ruiz P, Holers VM, Boackle SA, Colten HR, Gilkeson GS.
    J Immunol; 2000 Jan 15; 164(2):786-94. PubMed ID: 10623824
    [Abstract] [Full Text] [Related]

  • 11. Essential Roles for Mannose-Binding Lectin-Associated Serine Protease-1/3 in the Development of Lupus-Like Glomerulonephritis in MRL/lpr Mice.
    Machida T, Sakamoto N, Ishida Y, Takahashi M, Fujita T, Sekine H.
    Front Immunol; 2018 Jan 15; 9():1191. PubMed ID: 29892304
    [Abstract] [Full Text] [Related]

  • 12. Fc receptor-independent development of autoimmune glomerulonephritis in lupus-prone MRL/lpr mice.
    Matsumoto K, Watanabe N, Akikusa B, Kurasawa K, Matsumura R, Saito Y, Iwamoto I, Saito T.
    Arthritis Rheum; 2003 Feb 15; 48(2):486-94. PubMed ID: 12571859
    [Abstract] [Full Text] [Related]

  • 13. Complement receptor of the immunoglobulin superfamily reduces murine lupus nephritis and cutaneous disease.
    Lieberman LA, Mizui M, Nalbandian A, Bossé R, Crispín JC, Tsokos GC.
    Clin Immunol; 2015 Oct 15; 160(2):286-91. PubMed ID: 25988858
    [Abstract] [Full Text] [Related]

  • 14. Negative role of colony-stimulating factor-1 in macrophage, T cell, and B cell mediated autoimmune disease in MRL-Fas(lpr) mice.
    Lenda DM, Stanley ER, Kelley VR.
    J Immunol; 2004 Oct 01; 173(7):4744-54. PubMed ID: 15383612
    [Abstract] [Full Text] [Related]

  • 15. Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice.
    Lichtnekert J, Rupanagudi KV, Kulkarni OP, Darisipudi MN, Allam R, Anders HJ.
    J Immunol; 2011 Sep 15; 187(6):3413-21. PubMed ID: 21849682
    [Abstract] [Full Text] [Related]

  • 16. IL-12 deficiency in MRL-Fas(lpr) mice delays nephritis and intrarenal IFN-gamma expression, and diminishes systemic pathology.
    Kikawada E, Lenda DM, Kelley VR.
    J Immunol; 2003 Apr 01; 170(7):3915-25. PubMed ID: 12646661
    [Abstract] [Full Text] [Related]

  • 17. Piperlongumine alleviates lupus nephritis in MRL-Fas(lpr) mice by regulating the frequency of Th17 and regulatory T cells.
    Yao L, Chen HP, Ma Q.
    Immunol Lett; 2014 Sep 01; 161(1):76-80. PubMed ID: 24837470
    [Abstract] [Full Text] [Related]

  • 18. Icariin alleviates murine lupus nephritis via inhibiting NF-κB activation pathway and NLRP3 inflammasome.
    Su B, Ye H, You X, Ni H, Chen X, Li L.
    Life Sci; 2018 Sep 01; 208():26-32. PubMed ID: 30146016
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of the alternative complement pathway by antisense oligonucleotides targeting complement factor B improves lupus nephritis in mice.
    Grossman TR, Hettrick LA, Johnson RB, Hung G, Peralta R, Watt A, Henry SP, Adamson P, Monia BP, McCaleb ML.
    Immunobiology; 2016 Jun 01; 221(6):701-8. PubMed ID: 26307001
    [Abstract] [Full Text] [Related]

  • 20. Complement factor B inhibitor LNP023 improves lupus nephritis in MRL/lpr mice.
    Chen K, Deng Y, Shang S, Tang L, Li Q, Bai X, Chen X.
    Biomed Pharmacother; 2022 Sep 01; 153():113433. PubMed ID: 36076550
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.